•  
  •  
 

Author Credentials

Samantha A. Smith BS Nadim Bou Zgheib MD, FACOG Andrea M. Vallejos MD Jonathan D. Cuda MD

Author ORCID Identifier

https://orcid.org/0000-0001-8716-3264

DOI

10.33470/2379-9536.1294

Abstract

Leiomyosarcoma (LMS) of the vulva is rare. However it is the most common histologic subtype of vulvar sarcoma, accounting for approximately 1% of all vulvar malignancies. [1-8] Whether genetics and epigenetics play a role in pathogenesis is unclear. [1] The tumor is slow-growing with non-specific symptoms, has high metastatic potential, and follows a bimodal age distribution. [1-8] Diagnosis and prognosis are based upon immunohistochemical expression and criteria from early literature. [1,3,5-7] The most common therapeutic approach involves radical vulvectomy with lymph node resection. The value of adjuvant chemotherapy and radiation remains unknown. [1,3,5-8] Our case describes a 46-year-old Caucasian G2P2 female with LMS of the left labia.

Conflict(s) of Interest

The authors have no financial disclosures to declare and no conflicts of interest to report.

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

COinS